# A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

> **NCT05202405** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 64 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **DRUG:** AD-221
- **DRUG:** AD-221A and AD-221B

## Key facts

- **NCT ID:** NCT05202405
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-05
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05202405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05202405, "A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05202405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*